crifortinib besylate + daunorubicin + cytarabine

Crifortinib besylate + daunorubicin + cytarabine is a triple drug combination proposed for the treatment of acute myeloid leukemia (AML), particularly focused on patients with FLT3 mutations or high-risk disease subtypes. Crifortinib besylate is a small molecule FLT3 inhibitor that blocks the tyrosine-protein kinase receptor FLT3, suppressing leukemic cell proliferation and survival[1]. Daunorubicin is an anthracycline that intercalates into DNA, inhibits topoisomerase II, disrupts gene expression, and generates free radicals, resulting in cytotoxicity[2][4]. Cytarabine is an antimetabolite that inhibits DNA polymerase, targeting cells in the S-phase of the cell cycle[2][4]. Combination regimens of daunorubicin and cytarabine (often encapsulated in a liposomal formulation such as CPX-351) have demonstrated synergistic action and are established as standard induction chemotherapy options for AML[2][4][6]. This particular combination adds crifortinib besylate, augmenting conventional cytotoxic chemotherapy with targeted inhibition for enhanced disease control, particularly for FLT3-mutated AML.